Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and cancer. The company’s portfolio encompasses sequencing kits and reagents; sequencing tools and systems; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; instrument services, training, and consulting. The company serves pharmaceutical companies, academic institutions, genomic research centers, biotechnology companies, and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East, and Africa. Illumina is headquartered in San Diego, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Illumina Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Illumina Inc Company Overview
- Illumina Inc Company Snapshot
- Illumina Inc Pipeline Products and Ongoing Clinical Trials Overview
- Illumina Inc - Pipeline Analysis Overview
- Business Description
- Illumina Inc - Key Facts
- Illumina Inc - Major Products and Services
- Illumina Inc Pipeline Products by Development Stage
- Illumina Inc Ongoing Clinical Trials by Trial Status
- Illumina Inc Pipeline Products Overview
- Blood-Based Test - Breast Cancer
- Blood-Based Test - Breast Cancer Product Overview
- Blood-Based Test - Breast Cancer Clinical Trial
- Blood-Based Test - Lung Cancer
- Blood-Based Test - Lung Cancer Product Overview
- Blood-Based Test - Lung Cancer Clinical Trial
- Companion Diagnostic Test - Cancer
- Companion Diagnostic Test - Cancer Product Overview
- Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma
- Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma Product Overview
- Companion Diagnostic Test - Oncology
- Companion Diagnostic Test - Oncology Product Overview
- Companion Diagnostic Test - Pseudomonas Aeruginosa Infection
- Companion Diagnostic Test - Pseudomonas Aeruginosa Infection Product Overview
- Diagnostic Aid For Cancer (DAC) Test
- Diagnostic Aid For Cancer (DAC) Test Product Overview
- Explify Test - CNS Infections
- Explify Test - CNS Infections Product Overview
- Galleri Test
- Galleri Test Product Overview
- Galleri Test Clinical Trial
- HRD CDx Test
- HRD CDx Test Product Overview
- InfiniumDx CytoSNP-12 Assay
- InfiniumDx CytoSNP-12 Assay Product Overview
- Integrated MiniSeq System
- Integrated MiniSeq System Product Overview
- Lab-On-A-Chip
- Lab-On-A-Chip Product Overview
- Long Read Human Whole Genome Assay
- Long Read Human Whole Genome Assay Product Overview
- LSD-100 Lysosomal Storage Enzyme Analyzer
- LSD-100 Lysosomal Storage Enzyme Analyzer Product Overview
- Minimal Residual Disease Test
- Minimal Residual Disease Test Product Overview
- MRSA Screening Test
- MRSA Screening Test Product Overview
- Multiplexed Diagnostic Device
- Multiplexed Diagnostic Device Product Overview
- Next Generation Galleri
- Next Generation Galleri Product Overview
- NGS Diagnostic System
- NGS Diagnostic System Product Overview
- NGS-Based Transplant Diagnostic Assay
- NGS-Based Transplant Diagnostic Assay Product Overview
- NovaSeq 6000 Dx
- Product Status
- Novaseq Dx
- Novaseq Dx Product Overview
- Point-Of-Care Diagnostic Device - HIV
- Point-Of-Care Diagnostic Device - HIV Product Overview
- Portable Benchtop Analyzer - Viral Load Assay
- Portable Benchtop Analyzer - Viral Load Assay Product Overview
- TruSight NIPT
- TruSight NIPT Product Overview
- TruSight Oncology 500 - TP53 CDx Assay
- TruSight Oncology 500 - TP53 CDx Assay Product Overview
- TruSight Oncology 500 HRD
- TruSight Oncology 500 HRD Product Overview
- TruSight Oncology 500 HRD Clinical Trial
- TruSight Oncology Comprehensive
- TruSight Oncology Comprehensive Product Overview
- TruSight Oncology Comprehensive Clinical Trial
- TruSight Tumor 170 CDx - LOXO-101
- TruSight Tumor 170 CDx - LOXO-101 Product Overview
- TruSight Tumor 170 CDx - LOXO-292
- TruSight Tumor 170 CDx - LOXO-292 Product Overview
- Verifi Prenatal Test
- Verifi Prenatal Test Product Overview
- Illumina Inc - Key Competitors
- Illumina Inc - Key Employees
- Illumina Inc - Key Employee Biographies
- Illumina Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Recent Developments
- Illumina Inc, Recent Developments
- Jun 15, 2023: Breast Cancer Canada, AstraZeneca Canada and Illumina Join Forces To Launch Breast Cancer Screening and Detection Grants
- Jun 02, 2023: Illumina's Board of Directors elects two experienced Independent Directors to Board
- Jun 01, 2023: GRAIL and University of Oxford to Present Results From First Prospective Study of Multi-Cancer Early Detection in a Symptomatic Patient Population at 2023 ASCO Annual Meeting
- May 30, 2023: Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing
- Apr 25, 2023: Illumina reports financial results for first quarter of fiscal year 2023; announces commitment to accelerate margin growth
- Apr 19, 2023: GRAIL presents positive analytical validation data on its methylation-based post-diagnostic cancer research solution at American Association for Cancer Research (AACR) Annual Meeting 2023
- Apr 11, 2023: Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients
- Mar 27, 2023: Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease
- Mar 24, 2023: Illumina Issues Statement in Response to Carl Icahn's Letter
- Feb 02, 2023: Magistrate Judge issues favorable recommendation regarding Guardant Health’s Motion to dismiss lawsuit brought by Illumina
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Illumina Inc Pipeline Products and Ongoing Clinical Trials Overview
- Illumina Inc Pipeline Products by Equipment Type
- Illumina Inc Pipeline Products by Indication
- Illumina Inc Ongoing Clinical Trials by Trial Status
- Illumina Inc, Key Facts
- Illumina Inc, Major Products and Services
- Illumina Inc Number of Pipeline Products by Development Stage
- Illumina Inc Pipeline Products Summary by Development Stage
- Illumina Inc Ongoing Clinical Trials by Trial Status
- Illumina Inc Ongoing Clinical Trials Summary
- Blood-Based Test - Breast Cancer - Product Status
- Blood-Based Test - Breast Cancer - Product Description
- Blood-Based Test - Breast Cancer - Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection: The STRIVE Study
- Blood-Based Test - Lung Cancer - Product Status
- Blood-Based Test - Lung Cancer - Product Description
- Blood-Based Test - Lung Cancer - The SUMMIT Study: Cancer Screening Study with or Without Low Dose Lung CT to Validate a Multi-cancer Early Detection Test
- Companion Diagnostic Test - Cancer - Product Status
- Companion Diagnostic Test - Cancer - Product Description
- Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma - Product Status
- Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma - Product Description
- Companion Diagnostic Test - Oncology - Product Status
- Companion Diagnostic Test - Oncology - Product Description
- Companion Diagnostic Test - Pseudomonas Aeruginosa Infection - Product Status
- Companion Diagnostic Test - Pseudomonas Aeruginosa Infection - Product Description
- Diagnostic Aid For Cancer (DAC) Test - Product Status
- Diagnostic Aid For Cancer (DAC) Test - Product Description
- Explify Test - CNS Infections - Product Status
- Explify Test - CNS Infections - Product Description
- Galleri Test - Product Status
- Galleri Test - Product Description
- Galleri Test - A Study to Evaluate the Galleri Blood Test in the Multi-cancer Early Detection Test
- Galleri Test - REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri
- Galleri Test - The Circulating Cell-free Genome Atlas Study
- Galleri Test - The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-cancer Early Detection Test in an Eligible Screening Population
- Galleri Test - Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early Detection
- HRD CDx Test - Product Status
- HRD CDx Test - Product Description
- InfiniumDx CytoSNP-12 Assay - Product Status
- InfiniumDx CytoSNP-12 Assay - Product Description
- Integrated MiniSeq System - Product Status
- Integrated MiniSeq System - Product Description
- Lab-On-A-Chip - Product Status
- Lab-On-A-Chip - Product Description
- Long Read Human Whole Genome Assay - Product Status
- Long Read Human Whole Genome Assay - Product Description
- LSD-100 Lysosomal Storage Enzyme Analyzer - Product Status
- LSD-100 Lysosomal Storage Enzyme Analyzer - Product Description
- Minimal Residual Disease Test - Product Status
- Minimal Residual Disease Test - Product D
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies Inc
- Agilent Technologies Inc
- Oxford Nanopore Technologies Plc
- Roche Diagnostics International Ltd
- Qiagen NV
- ChunLab Inc
- Thermo Fisher Scientific Inc
- Luminex Corp
- Qiagen NV
- Oxford Nanopore Technologies Plc
- Thermo Fisher Scientific Inc
- ChunLab Inc
- Luminex Corp
- Roche Diagnostics International Ltd
